PHARMACEUTICAL 2025

Alnylam Pharmaceuticals INC
Rank 144 of 225



PHARMACEUTICAL 2025

Alnylam Pharmaceuticals INC
Rank 144 of 225

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 5.3% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 74% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	3,295,285
Cost of Goods Sold	306,513
Intangible Assets	0
Liabilities, Current	1,186,272
Liabilities, Non-Current	627,649
Other Assets	441,914
Other Compr. Net Income	-11,143
Other Expenses	-82,361
Other Liabilities	2,358,974
Other Net Income	-200,490
Other Revenues	2,248,243
Property and Equipment	502,784
Research and Development	1,126,232
Selling, General and Administrative Expense	975,526

Output Variable	Value in 1000 USD
Assets	4,239,983
Liabilities	4,172,895
Expenses	2,325,910
Revenues	2,248,243
Stockholders Equity	67,088
Net Income	-278,157
Comprehensive Net Income	-283,728
BaseVar	6,599,332
ECR before LimitedLiability	-3.3%
Economic Capital Ratio	141%